Chiron Corporation announced at a presentation at the 23rd Annual JPMorgan Healthcare Conference that the company anticipates that the UK Medicines and Healthcare products Regulatory Agency (MHRA), acc
Centocor, Inc., announced today that more than a half million patients worldwide have now been treated with the anti-TNF agent REMICADE? (infliximab) since it was introduced in the United States five years ago. With m
Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions. In this phase II clinical trial, the research
Depomed, Inc. today announced top line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract i
Nearly 1.3 million Americans 12 and older abuse prescription drugs and require treatment for their problem, a new study concludes. Older
The U.S. Food and Drug Administration (FDA) has announced a joint public meeting of the agency's Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee to be held February
Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metas
Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Menactra (Meningococcal [Groups A, C, Y and W-
FDA has approved Apokyn (apomorphine) as an injectable drug for treating Parkinson's patients during episodes of "hypomobility," so-called "off periods" in which the patient becomes
New analysis from Frost & Sullivan,
The letter has been provided in response to FDA instructions issued on the 19th of May 2004 regarding Janssen's "Dear Healthcare Provider" (DHCP) Letter for RISPERDAL? (risperidone) disseminated by Janssen Pharmaceutica, Inc. on November 10, 2003.
The FDA advised that the DHCP was misleadingly and failed to provide material information about RISPERDAL??, which minimized potentially fatal risks associated with the drug. The DHCP also claimed to be safer than other drugs in its class without adequate substantiation.
"RISPERDAL? is indicated for the treatment of schizophrenia and for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder. RISPERDAL? is also indicated in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder," according to background information on the drug RISPERDAL?, issued by the FDA in its warning letter. It is approved for use as therapy alone or in combination with drugs called mood stabilizers, such as lithium or valproate.
More than 10 million people use RISPERDAL? which accounts for around $2 billion in annual sales for Janssen Pharmaceutica Products
Janssen Pharmaceutica Products is backed by Johnson & Johnson, its parent company.